C-VWJZCircumvent Pharma
precision medicines, palmitoylome modulation, neurodegeneration
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-VWJZ
C-VWJZC-VWJZprecision medicines, palmitoylome modulation, neurodegeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Circumvent states that neurodegenerative disease is a growing global cause of death and that progress on disease-modifying treatments has been limited by a lack of novel insight into the underlying driver mechanisms. The company says it was formed to develop precision medicines for neurodegenerative disease, beginning with Batten Disease, and believes that studying high-fidelity disease models has revealed shared brain-cell dysfunction across multiple neurological disorders that can be translated into therapies with broad potential.
SourceCircumvent Pharmaceuticals states that it is tackling neurodegenerative disease by targeting heritable forms of neurodegeneration, with the belief that this approach can enable drug discovery and development for both rare and common neurodegenerative diseases.
SourceNo company beliefs, mission statement, or scientific theory are visible in the provided 2018-08-24 Wayback snapshot text. The visible content consists only of Internet Archive Wayback Machine interface and crawl metadata, so there is no explicit company stance to extract from this capture alone.
SourceThe provided visible text only shows the Internet Archive Wayback header and capture metadata, not the company page’s actual content, so no company belief, stance, or theory can be extracted reliably from the text supplied.
Source